At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 53 enrolled
Drug / intervention
MEK162 +1 moredrug
Likely dose
MEK162 45 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase Ib/II, Open-label, Multi-center, Dose Escalation Study of MEK162 in Combination With Panitumumab in Adult Patients With Mutant RAS or Wild-type RAS Metastatic Colorectal Cancer
In Brief
A Phase 2 clinical trial evaluating MEK162 and Panitumumab for Metastatic Colorectal Cancer. Completed, enrolled 53 participants across 8 sites in 7 countries.
Detailed Summary
The primary purpose of the phase Ib is to estimate the MTD/RPD2 and of the phase II is to assess the anti-tumor activity of MEK162 in combination with panitumumab.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Colorectal Cancer
CountriesBelgium, Canada, France, Italy, Netherlands, Spain, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedAug 2013
Enrollment StartNov 2013
Primary CompletionJan 2016
TodayJul 2026
First PostedAug 22, 2013
Enrollment StartNov 19, 2013
Primary CompletionJan 25, 2016
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 12.9 years ago
Interventions
MEK162drug
Tablet for oral use, 45 mg (three 15 mg tablets), BID
Panitumumabdrug
Intravenous infusion, 20mg/ml concentrate solution for infusion, Q2W (Days 1 and 15 of every cycle)